CASE REPORT  OPEN

Potential of ultra-high-resolution photon-counting CT of bone metastases: initial experiences in breast cancer patients

E. Wehrse1,2,3, S. Sawall2,3, L. Klein4, P. Glemser1, S. Delorme1, H.-P. Schlemmer1, M. Kachelrieß2,3, M. Uhrig1, C. H. Ziener6 and L. T. Rotkopf6

Conventional computed tomography (CT) scanner detectors consist of distinct detector elements1, with each of these elements hosting a scintillator that converts the incoming x-ray photon’s energy into visible light and a photodiode for the light registration. The generated and registered electrical signal corresponds to the total amount of absorbed and converted energy regardless of the number and individual energy of the incoming x-ray photons. Accordingly, the measured signal corresponds to the integrated, i.e., total amount of x-ray photon energy deposited in the detector volume in the specific intervals of each subsequent measurement.

Photon-counting detectors (PCDs), on the other hand, consist of a single layer semiconductor diode without the use of a dedicated scintillator2, directly converting a photon’s energy into a measurable charge cloud, corresponding to the photon’s energy. As the resulted signal is in the range of tens of nanoseconds3,4, small-sized detector pixels and advanced read-out electronics can be constructed to successfully discriminate photons reaching the detector almost simultaneously at high clinical x-ray flux rates5,6.

Photon-counting computed tomography (PCD CT) is therefore capable of counting single x-ray photons and discriminating them according to their energy6-9. Measurement of photon energy might especially be beneficial if it is combined with potential novel contrast agents consisting of medium-to-high atomic number elements, such as iodine, gadolinium, ytterbium, and bismuth7,8,10,11. These are currently being investigated and may allow for single-acquisition multi-phase imaging12,13.

Because of the aforementioned small pixels, current PCD CT scanners achieve a higher in-plane and longitudinal spatial resolution1 than conventional clinical energy-integrating detector (EID) CT, namely, up to 150 µm14. In combination with large image matrix reconstructions, improvements in the detection and visualization of higher-order bronchi15 and small pulmonary vessels16 as well as of the human inner ear and temporal bone16,17 are reported, whereas experience in clinical benefits in oncological imaging is still pending.

Breast cancer, the most common cancer among women, has a high incidence of bone metastases (BM), which is the most common distant form of metastasis18-20. They cause significant morbidity by fractures, hypercalcemia, and spinal cord compression as well as considerable mortality21, with mortality hazard ratios of five to six when compared to breast cancer patients without BM22.

Treatment of BM is of utmost importance, as skeletal complications can determine patients’ outcome and quality of life22,23. For response assessment of BM, several imaging modalities are available23,24. In planar bone scanning, 99mTc-diphosphonate bone scanning, and positron emission tomography (PET) alone, most BMs cannot be assessed25. Hybrid imaging techniques, such as single-photon emission computed tomography/CT (SPECT/CT), PET/CT, and PET/magnetic resonance imaging (MRI) with bone-specific tracers like 18F-NaF or tumor-specific tracers like 18F-FDG achieve higher accuracies26. However, these modalities are more costly and are less widely available. Whole-body MRI acquisitions with diffusion weighted imaging and supporting T1- and T2-weighted sequences are also being investigated27 and reveal millimetric resolution28. Because PCDs have been developed for clinical flux rates, the examination times for PCD CT do not differ significantly from EID CT, e.g., in the order of minutes for the whole procedure including positioning for whole-body acquisitions with submillimeter resolution. For osteoplastic and osteolytic bone lesions, the resolution improvement achieved with PCD CT can potentially be used to better differentiate between real tumor

1Division of Radiology, German Cancer Research Center, Heidelberg, Germany. 2Medical Faculty, Ruprecht-Karls-University Heidelberg, Heidelberg, Germany. 3Division of X-Ray Imaging and Computed Tomography, German Cancer Research Center, Heidelberg, Germany. 4email: e.wehrse@dkfz-heidelberg.de

Published in partnership with the Breast Cancer Research Foundation
growth and therapy-associated sclerotic changes, i.e., pseudoprogression, as PCD CT reaches resolutions comparable with bone trabecular diameters\(^3\) and high-resolution images may allow for the detection of metastatic changes in shorter intervals.

After installation of a prototype PCD CT scanner in our institution, we are conducting an ongoing pilot study to gain insight in the potential advantages of this technique in various organs and diseases, intendedly exploiting its potential regarding resolution and signal-to-noise ratio. From this cohort, we extracted a subset of patients with advanced metastasized breast cancer to investigate the potential advantages of PCD CT imaging in assessing BMs. Examinations were performed on an experimental whole-body PCD CT (SOMATOM CounT), which is based on a SOMATOM Definition Flash dual-source CT scanner housing a prototype PCD and a conventional EID (Siemens Healthineers, Germany) that exclusively serves to obtain data from outside the limited field of view (FOV) covered by the PCD.

### RESULTS

#### Population characteristics

Four female patients diagnosed with late-stage osteoplastic metastasized breast cancer were examined, median age 61 years (45–68 years). The initial diagnosis was 14.5 years before the examination (2–23 years). Detailed grading and histological analysis results at the time of initial diagnosis are listed in Table 1.

#### Patient 1

**Case history.** The patient was first diagnosed in spring 2017 at the age of 42 years with a high-grade primary small cell carcinoma of the right breast, a subtype of the rare neuroendocrine breast cancer\(^3\). At diagnosis, the tumor had spread to the lymph nodes and exhibited both high estrogen receptor (ER) expression as well as high Ki-67 expression (Table 2). The patient received neoadjuvant chemotherapy consisting of etoposide and cisplatin before undergoing a modified radical mastectomy followed by radiation therapy of the resection bed and axilla 7 months after initial diagnosis. In summer 2019, she complained of increasing pain in the pelvis when receiving a routine ultrasound exam of the breast in our center. An abdominal CT demonstrated a large osteolytic BM in the left iliac bone, which was confirmed by a local biopsy. The lesion was irradiated in the following month and the patient remained on the postoperative regimen of letrozole and goserelin and was started on zoledronic acid. Eighteen months after initial diagnosis, the patient underwent both conventional CT and a PCD CT scan focused on the iliac BM in a span of 2 weeks (Fig. 1a–d). Three months later, another CT staging was performed (Fig. 1e).

Since then, therapy and diagnostic follow-up has been continuing unchanged except for a 3-month course of leuprorelin acetate.

#### Imaging discussion.

Comparing conventional CT images of the osteolytic bone lesion (asterisk (*) in Fig. 1c–e) with PCD CT images demonstrates the benefit of higher spatial resolution in assessing structural bone changes and trabecular disruption. Comparing the dorsal borders of the lesion, PCD CT allows a clear depiction of

### Table 1. Reader’s opinion on different features in EID and PCD CT images.

| Item                                                                 | Reader’s opinion | Improved to EID CT | Neutral | Inferior to EID CT |
|---------------------------------------------------------------------|------------------|--------------------|---------|--------------------|
| Pat. 1, Osteolytic lesion (see Fig. 1a–e)                            |                  |                    |         |                    |
| Visualization of the lesion’s margin                               | 4                | 0                  | 0       |
| Visualization of the lesion’s content (*)                          | 4                | 0                  | 0       |
| Assessment of iliac cortical bone                                  | 3                | 1                  | 0       |
| Pat. 2, Osteoplastic lesion (see Fig. 2) and of PC and EID CT image stack |                  |                    |         |                    |
| Visualization of the lesion’s architecture                         | 4                | 0                  | 0       |
| Assessment of the smallest focal lesions in the whole-image stack  | 4                | 0                  | 0       |
| Overview of tumor load and distribution in PC and EID CT image stack | 3                | 1                  | 0       |
| Pat. 3, Fifth lumbar vertebra (see Fig. 3a, b)                      |                  |                    |         |                    |
| Discrimination of trabeculae from each other                       | 4                | 0                  | 0       |
| Assessment of ventral formation of osteophytes                     | 4                | 0                  | 0       |
| Pat. 4, Osteoplastic metastasis (red arrow in Fig. 3d) and the left iliac bone |                  |                    |         |                    |
| Visualization of the lesion’s margin                               | 4                | 0                  | 0       |
| Assessment of iliac spongiosa                                     | 3                | 1                  | 0       |

### Table 2. Patient and tumor characteristics at the time of initial diagnosis.

| Pat. Disease             | ER status | PR status | Her2neu status | Ki-67 | T  | N  | M  | L  | G  | Chemotherapy schemes at the time of image acquisition |
|--------------------------|-----------|-----------|----------------|-------|----|----|----|----|----|---------------------------------|
| 1 Primary small cell carcinoma | Pos.     | Pos.     | Neg.           | 90%   | cT3| cN+| –  | –  | G3  | Goserelin + letrozole            |
| 2 ILC                    | Pos.     | Pos.     | Pos.           | 5–10% | pT2| pN0| M0 | –  | G2   | Capecitabine                   |
| 3 IDC                    | Pos.     | Pos.     | Neg.           | 25%   | pT1c| pN0| –  | –  | Liposomal doxorubicin           |
| 4 NST                    | Pos.     | Pos.     | Neg.           | 20%   | pT1c| pN0| L0 | G2  | Liposomal doxorubicin           |

**ILC** invasive lobular carcinoma, **IDC** invasive ductal carcinoma, **NST** no special type carcinoma.
trabecular lysis, while conventional CT shows only blurred border structures. In addition, the loss of trabecular density in the left ala of the sacrum can be clearly seen on PCD CT. The visualization of the lesion’s content and margin was improved in PCD CT images in comparison to EID CT images according to the reader’s opinion (Table 1). Minor alterations of the iliac spongiosa, such as the small osseous defect in the medial iliac bone (red circle in the PCD CT image Fig. 1c) are hardly visible in EID CT images due to the noise grain size.

Patient 2
The patient was first diagnosed with unifocal, medium-grade breast cancer in autumn 1996 at the age of 45 years. Histological staining revealed ER and progesterone receptor expression of immune reactive score 4 and 6, respectively (Table 2). Due to the relatively young age, the low hormone receptor expression, and a small tumor size, a cyclophosphamide, methotrexate, and 5-fluorouracil scheme was started after breast-conserving surgery and corresponding radiation therapy. Fifteen years later, multiple subsolid lung nodules were discovered and histopathologically confirmed to be metastases of the original tumor. The patient was subsequently randomized to receive either fulvestrant or fulvestrant combined with ribociclib (blinded). Over the next 2 years, she developed local recurrence and osteoplastic BMs mainly to the lumbar spine and pelvis. Following, she received repeated radiotherapy of the right axilla and medical treatment was changed to letrozole, zolendronic acid, and finally to palliative oral capecitabine. In July 2019, a routine E1 CT staging was performed, followed by PCD CT examination 1 week later.
Imaging discussion. As can be seen in Fig. 2a, the patient had multiple disseminated osteoplastic bone lesions of varying size. Due to the relatively coarse trabecular structure lateral to the sacroiliac joint, differentiation of small metastases and benign focal changes is compromised due to partial volume effects. PCD CT allows an accurate depiction even of small focal lesions and their content (Fig. 2b–e, g). Figure 2f, g show an osteoplastic lesion in the fifth lumbar vertebra. An inner core and an outer sclerotic border can clearly be discriminated in both CT images, while the characterization of the tissue in between is improved in PCD CT images, according to the readers’ opinion (Table 1).

Patient 3

Case history. The female patient was originally diagnosed with unifocal, low-grade breast cancer of the right breast in 2004 at the age of 50 years (Table 2). Following breast-conserving therapy and adjuvant radiation therapy, the patient was treated with letrozole and tamoxifen. Five years later, a ductal carcinoma in situ of the left breast was removed following the same procedure. Eleven years after initial diagnosis, breast cancer metastases were found in the right axilla.

CT staging showed disseminated osteoplastic BMs. Over the next 3 years, she received different regimens, including letrozole, palbociclib, vinorelbine, 5-flourouracil, fulvestrant, and ribociclib. In addition, she underwent external radiation to the frontal bone and of a singular hepatic metastasis. Forty-three months after initial diagnosis of the osseous lesions, the patient underwent conventional CT staging followed by a PCD CT of the lumbar spine a month later.

Imaging discussion. In contrast to the previous patient, Fig. 3a, b demonstrates an almost complete infiltration of the fifth lumbar vertebral body by osteoplastic metastases leading to coarsening...
of the vertebral trabeculae. At the ventral border of the vertebral body, a single row of degenerative osseous outgrowth is visible. Assessment on image features is listed in Table 1. Again, the possibility of visualizing single trabeculae may allow a more accurate assessment of the metastatic process.

Patient 4

Case history. The patient was initially diagnosed with unifocal hormone receptor-positive breast cancer of the right breast in summer 2005 at the age of 43 years (Table 2). After a breast-sparing mastectomy, radiation therapy, and adjuvant antihormonal therapy, the patient remained symptom-free until 2015, when she noticed increasing pain along the whole spine. A CT scan showed disseminated osseous metastases in the whole axial skeleton as well as a suspicious lung nodule, which turned out to be a metastasis of the before-mentioned breast cancer. Due to the advanced disease, palliative therapy including radiotherapy of several vertebrae and ribs and letrozole was started. Varying
chemotherapy schemata followed, which failed to significantly inhibit tumor growth. Due to an increasing hepatic tumor load, the general condition worsened. Sadly the patient passed away in December 2019, 14 years after the initial cancer diagnosis.

**Imaging discussion.** In Fig. 3c, d, several osteolytic metastases of varying size and structure along the left iliacosacral joint are depicted. In the PCD CT image, it is clearly visible that the tumor spiculae of the central metastasis in the medial margin are oriented in parallel to the trabecular structure. According to the readers’ opinion, the fine structure of the iliac spongiosa is better assessable in the PCD CT images (Table 1).

*Inter-reader variability in the assessment of lesion sizes.** Lesion sizes show relative deviations from the mean in the order of 20%. In 10 out of 15 total lesions (66.7%), the root-mean-squared error (RMSE) was lower in the PCD CT images, as demonstrated in Fig. 3e.

**DISCUSSION**

This case series illustrates the value of PCD detectors in assessing bone lesions in metastasized breast cancer. This detector allows, at the same dose, taking images with significantly higher spatial resolution. Among others, this is reflected by smaller noise grain sizes. Using PCD CT high-resolution kernels, overshoots and undershoots often observed at sharp edges in EID CT using sharp kernels is reduced, resulting in a more subtle image impression that is apparently favored by the majority of the readers. Tumor margins can be depicted much clearer and assessment of the structural integrity of remaining trabecular bone becomes easier. As the remaining components including the x-ray tubes of this PCD CT scanner are identical to standard clinical CT scanners, risk of technical failure is kept at a minimum, leaving essentially no significant downsides to upgrading the detector.

Without nuclear medicine techniques, assessing the response of BMs to treatment relies mainly on morphological criteria. For example, the MD Anderson bone response criteria assign complete response only when the previously osteolytic lesion shows complete sclerotic fill-in, while partial response is assigned in cases of only incomplete fill-in or development of a sclerotic rim. It is therefore vital to depict structural bone changes even in small lesions, a task that remains challenging for lesions that do not exceed the standard voxel size by at least a magnitude. Still, while several studies have investigated the use of PCD for clinical applications, no larger clinical studies utilizing PCD are required before widespread adoption becomes possible.

This study has limitations. The examination protocol was adapted from high-resolution EID CT protocols used for temporal bone and inner ear imaging, and is as such not directly transferable to whole-body examinations. Since the focus of this study was not a direct comparison with EID CT but to explore new potential clinical applications, dose levels were not matched to clinical EID CT levels. A recently published study focusing on sinus and temporal bone examination utilized comparable doses. The current experimental implementation of the PCD into an existing dual-source EID CT scanner suffers from technical limitations, which are no general limitation of the PCD technology itself. Among others, the axial FOV and also the Z-coverage, with the latter resulting in slower scan speeds, are limited. Furthermore, the available image reconstruction and post-processing options are not yet fully available and the detector elements are currently read out in groups of 2×2 pixels, due to restricted data transfer rates.

Quantitative material images, such as calcium images and virtual non-calcium maps, would allow for an improved visualization, assessment of the lesions’ content, and a precise quantification of therapy results. For longitudinal studies, the calcium density has to be corrected to a varying fat portion in the bone marrow, which is possible by dual-energy CT. As theoretically predicted and experimentally shown, single-source PCD CT is inferior at least to the latest dual-source EID CT systems regarding spectral separation, due to different x-ray source spectra and prefiltration in the latter. Additionally, current PCD CT systems are compromised by spectral distortions and non-ideal physical effects. Combining PCDs and technologies such as dual-source CTs may therefore lead to additional improvements and may facilitate further dose reductions.

In parallel with technical modifications, clinical investigations have to focus on several questions. In future follow-up examinations, morphological and spectral differences between bone lesions with vital metastases and reactive sclerosis due to systemic therapy or radiotherapy have to be investigated systematically.

In conclusion, while research into potential clinical applications is ongoing, and key applications have yet to be identified, the higher resolution and improved image quality of PCD CT images potentially offers benefits for the assessment of BMs of breast cancer.

**METHODS**

**Study design**

This prospective case series was approved both by the Ethics Committee of the Medical Faculty of Heidelberg according to the Declaration of Helsinki of 2013 and the Federal Office for Radiation Protection, and all patients gave their informed consent (German Clinical Trials Register DRKS00017759). Candidates for PCD CT imaging were selected from patients undergoing regular oncological follow-up examinations in our clinic with Eastern Cooperative Oncology Group performance status of 0–2, histologically confirmed breast cancer, and BMs in the pelvis or lumbar spine between July and October 2019. For comparison, we used clinical routine EID CT images acquired before and after the PCD CT exams. Lesions previously detected in these EID CT scans were selected as target lesions, which were placed in the center of the scan volume in the PCD CT scans.

**CT imaging and image analysis**

All patients underwent routine contrast-enhanced CT staging at a SOMATOM Definition Flash (Siemens Healthineers, Germany) dual-source CT scanner operating either in single-energy mode (one patient) or dual-energy mode (three patients), as listed in Table 3. Tube current time products per source ranged from 90 to 235 mAs. For dual-energy scans, both detector signals were averaged for improving signal-to-noise ratios. PCD CT acquisitions were performed with 300 mAs using the ultra-high-resolution mode of the PCD (0.25 mm pixel size in the isocenter). Additionally, a data completion scan (120 kV, 30 mAs, 25 mGycm, CTDI of 2.1 mGy) was done to avoid truncation artifacts caused by the limited field of measurement of the experimental PC detector. For axial images, reconstruction was performed using a routine B80f kernel for conventional CT and a high-resolution UB8f kernel for PCD CT and pixel size of 0.3×0.3 mm with 1 mm slice thickness. The maximal scan length was fixed at 10 cm in craniocaudal direction.

**Reader study**

Two board-certified radiologists (9 and 8 years of experience in oncologic imaging) and two residents (1 year experience in oncologic imaging) assessed volumetric image stacks of PCD CT and conventional CT on a standard clinical reading console with patient identity blinded and in randomized order. Due to differences in FOV, acquisition parameters, and spatial resolution, the CT modality could not be blinded. Viewing parameters were freely adjustable and images in axial, coronal, and sagittal reformation were provided. Characteristic image sections were rated with respect to specific parameters (detailed below) and graded on a three-point Likert scale. The results of the survey are demonstrated next to the image section. Additionally, the readers were prompted to determine the area of 15 focal osteoplastic lesions (10 lesions from Pat. 2 and 5 lesions from Pat. 4, sizes ranging from 30 to 1500 mm²) by measuring the long and short axes as per RECIST guidelines.

**Statistics**

All statistical analyses were performed using Python 3.8 (Python Software Foundation). Parameters were compared as absolute quantities and
relative percentage points. Due to the low number of both images and readers, no significance testing was done.

For the inter-reader variability of the different lesion sizes, we calculated the relative RMSE according to RMSE $= \sqrt{\frac{\sum_{i=1}^{n} \left( \frac{s_i - \bar{s}}{\bar{s}} \right)^2}{n}}$ with $s_i$ as the lesion area and $\bar{s}$ as the mean lesion area over all readers.

**Reporting summary**
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

**DATA AVAILABILITY**
The data generated and analyzed during this study are described in the following data record: https://doi.org/10.6084/m9.6.12798114. All demonstrated CT images are available as part of the data record as pseudonymized DICOM files. The acquisition and reconstruction parameters are available as metadata in each file so any user will be able to adapt the CT window. These DICOM files underlie Figs. 1 and 2 and Table 3. The file names include the figures to which they apply. Additionally, the Excel spreadsheet npj_breast_cancer_PCCT_Reader-Study.xlsx, which is also part of the data record, contains the lesions diameters according to the four readers. All readers are co-authors on the related manuscript and allow the publication of their assessments. All data on the reader’s opinion on different features in EID and PCD CT images are presented in Table 1 of the related manuscript. The patient and tumor characteristics at the time of initial diagnosis, which are contained in Table 2 of the related manuscript, are data from given physicians’ letters, and so cannot be shared without jeopardizing patients’ anonymity. Any requests for access to this data should be made to the corresponding author.

**CODE AVAILABILITY**
All statistical analyses were performed using standard statistical libraries in Python 3.8 (Python Software Foundation). Code is available on reasonable request from any qualified researcher.

Received: 6 April 2020; Accepted: 12 November 2020; Published online: 04 January 2021

**REFERENCES**

1. Willemink, M. J., Persson, M., Pompom, M., Pourmorteza, A., Pelc, N. J. & Fleischmann, D. Photon-counting CT: technical principles and clinical prospects. Radiology 289, 293–312 (2018).
2. Kappler, S., Glasser, F., Janssen, S., Kraft, E. & Reinwand, M. A research prototype system for quantum-counting clinical CT. Proc. SPIE 7622, 76221Z (2010).
3. Zambon, P. et al. Spectral response characterization of CdTe sensors of different pixel size with the IBEX ASIC. Nucl. Inst. Methods Phys. Res. A 892, 106–113 (2018).
4. Klein, L. et al. Effects of detector sampling on noise reduction in clinical photon-counting whole-body computed tomography. Invest. Radiol. 55, 111–119 (2020).
5. Taguchi, K. Energy-sensitive photon counting detector-based X-ray computed tomography. Radiol. Phys. Technol. 10, 8–22 (2017).
6. Ivaneczyk, J. S. et al. Photon counting energy dispersive detector arrays for X-ray imaging. IEEE Trans. Nucl. Sci. 56, 535–542 (2009).
7. Schomla, J. P. et al. Experimental feasibility of multi-energy photon-counting K-edge imaging in pre-clinical computed tomography. Phys. Med. Biol. 53, 4031–4047 (2008).
8. Si-Mohamed, S. et al. Review of an initial experience with an experimental spectral photon-counting computed tomography system. Nucl. Instrum. Methods Phys. Res. A 873, 27–35 (2017).
9. Cormode, D. P. et al. Multicolor spectral photon-counting computed tomography: In vivo dual contrast imaging with a high count rate scanner. Sci. Rep. 7, 1–11 (2017).
10. Rolf, S. et al. Photon-counting CT for simultaneous imaging of multiple contrast agents in the abdomen: an in vivo study. Med. Phys. 44, 5120–5127 (2017).
11. Yeh, B. M. et al. Opportunities for new CT contrast agents to maximize the diagnostic potential of emerging spectral CT technologies. Adv. Drug Deliv. Rev. 113, 201–222 (2017).
12. Symons, R. et al. Photon-counting CT for simultaneous imaging of multiple contrast agents in the abdomen: An in vivo study. Med. Phys. 44, 5120–5127 (2017).
13. Si-mohamed, S. et al. Spectral photon-counting computed tomography (SPCCT): phase liver imaging with a dual contrast agent protocol. Sci. Rep. 9, 1–8 (2019).
14. Leng, S. et al. 150-μm Spatial resolution using photon-counting detector computed tomography technology: technical performance and first patient images. Invest. Radiol. 53, 655–662 (2018).
15. Bartlett, D. J. et al. High-resolution chest computed tomography imaging of the lungs: impact of 1024 matrix reconstruction and photon-counting detector computed tomography. Invest. Radiol. 54, 129–137 (2019).
16. Pourmorteza, A., Symons, R., Henning, A., Ulzheimer, S. & Bluemke, D. A. Dose efficiency of quarter-millimeter photon-counting computed tomography: first-in-human results. Invest. Radiol. 53, 365–372 (2018).
17. Rajendran, K. et al. Dose reduction for sinus and temporal bone imaging using photon-counting detector CT with an additional tin filter. Invest. Radiol. 55, 91–100 (2020).
18. Scheid, V., Buzdar, A. U., Smith, T. L. & Hortobagyi, G. N. Clinical course of breast cancer patients with osseous metastasis treated with combination chemother-apy. Cancer 58, 2589–2593 (1986).
19. Coleman, R. E. et al. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12, 6243s–6249s (2006).
20. Kennecke, H. et al. Metastatic behavior of breast cancer subtypes. J. Clin. Oncol. 28, 3271–3277 (2010).
21. Yong, M. et al. Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999-2007). Breast Cancer Res. Treat. 129, 495–503 (2011).
22. Sathiakumar, N. et al. Mortality following bone metastases and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1992-2006. Breast Cancer Res. Treat. 131, 231–238 (2012).
23. Brown, J. E., Cook, R. J., Lipton, A., Costa, L. & Coleman, R. E. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res. Treat. 123, 767–779 (2010).
24. Iagaru, A., Minamimoto, R., Spect, S., Pet, C. T. & Ct, P. E. T. Nuclear medicine imaging techniques for detection of skeletal metastases in breast cancer. Positron Emiss. Tomogr. 13, 383–393 (2018).
25. Cook, G. J. R., Azad, G. K. & Goh, V. Imaging bone metastases in breast cancer: staging and response assessment. J. Nucl. Med. 57, 27–33 (2016).
26. Rager, O. et al. Accuracy of whole-body HDP SPECT/CT, FDG PET/CT, and their combination for detecting bone metastases in breast cancer: an intra-personal comparison. Am. J. Nucl. Med. Mol. Imaging 8, 159–168 (2018).
27. Id. A. S., Trisoglio, A., Scolo, E., Berardo, S. & Carrieri, A. Whole-body MRI with diffusion-weighted imaging in bone metastases: a narrative review. Diagnostics 8, 45 (2018).
28. Petralia, G. et al. Whole-body magnetic resonance imaging (WB - MRI) in oncology: recommendations and key uses. Radiol. Med. 124, 218–233 (2019).
29. Pasogliou, V., Michoux, N., Larbi, A., Van Nieuwenhove, S. & Lecouvet, F. Whole body MRI, and oncology: recent major advances. J. Radiol. 1, 6–8 (2018).
30. Eckstein, F. et al. Sex differences of human trabecular bone microstructure in aging are site-dependent. J. Bone Miner. Res. 22, 817–824 (2007).
31. Abou Dalle, I., Abbass, J., Boulos, F., Salem, Z. & Assi, H. I. Primary small cell carcinoma of the breast: A case report. J. Med. Case Rep. 11, 1–5 (2017).
32. Costelloe, C. M., Chuang, H. H., Madewell, J. E. & Ueno, N. T. Cancer response criteria and bone metastases: RECIST 1.1, MD Anderson and PERIST. J. Cancer 1, 80–92 (2010).

Table 3. Acquisition and reconstruction parameters for this study (if not mentioned otherwise).

| Scan mode | EID | PCD |
|-----------|-----|-----|
| Scan type | Spiral | Sequential |
| Rotation time | 0.5 s | 1.0 s |
| Collimation | $32 \times 0.6$ | $32 \times 0.25$ |
| Pitch | 0.6 | – |
| Tube voltage | 100 kV/140 kV + Sn or 100 kV | 120 kV |
| Effective tube current | 90–235 mAs per source | 300 mAs |
| CARE DOSE 4D | ON | OFF |
| CTDI | 7.0–14.4 mGy | 24.3 mGy |
| Recon algorithm | wFBP | wFBP |
| Recon kernel | 800f | U80f |
| Slice thickness | 1 mm | 1 mm |
| Slice increment | 0.5 mm | 0.5 mm |
| In-plane pixel size | 0.3 mm × 0.3 mm | 0.3 mm × 0.3 mm |
| Display window | $[C = 500 \text{ HU}, W = 1500 \text{ HU}]$ | $[C = 500 \text{ HU}, W = 1500 \text{ HU}]$ |

Published in partnership with the Breast Cancer Research Foundation

npj Breast Cancer (2021) 3
ACKNOWLEDGEMENTS

No funding was received for this work. The authors thank Dr. Sebastian Faby, Siemens Healthineers, Erlangen, Germany for stimulating discussions and critical review of the manuscript.

AUTHOR CONTRIBUTIONS

E.W. and C.H.Z. did patient acquisition and information. E.W. and L.T.R. performed image analysis, wrote the manuscript, and participated in the reader study. P.G. and C.H.Z. participated in the reader study and critically revised the manuscript for content. S.S. and L.K. did image reconstruction, PCD CT calibration, and quality measurements. S.F., S.D., H.-P.S., M.K., and M.U. critically revised the manuscript for content. M.U. did the application for approval of the study by the Ethics Committee of the Medical Faculty of Heidelberg and the Federal Office for Radiation Protection. All authors provided critical feedback and helped shape the research, analysis, and manuscript.

FUNDING

Open Access funding enabled and organized by Projekt DEAL.

COMPETING INTERESTS

The authors declare no competing interests.

ADDITIONAL INFORMATION

Supplementary information is available for this paper at https://doi.org/10.1038/s41523-020-00207-3.

Correspondence and requests for materials should be addressed to E.W.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021